From complexity to clarity in cell and gene therapy
One of the most exciting frontiers in medicine, cell and gene therapies are already offering breakthrough treatments and potential cures in severe genetic diseases and cancer. The innovations continue to advance rapidly, with press releases announcing major breakthroughs on a seemingly monthly basis.  It ’s undoubtedly a good news story but these advances bring with them the challenge of explaining all the exciting, but complex possibilities to patients and caregivers.  The groups that have historically been expected to help keep doctors up to speed cannot be expected to do so in this dynamic environm...
Source: EyeForPharma - September 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Australia ’s field force: evolving on fast forward
The pandemic has, it will surprise no one, upended traditional ways of working for pharma ’s Australian field force. “I don't think that we will ever go back to working the way we did pre-COVID, ” says David Grolman, Medical Director at Pfizer Australia and New Zealand.”   But arguably this is less of a revolution than it might first seem. The havoc and disruption it has wreaked has merely accelerated change that was happening anyway, much of it positive, says Matthew Britland, VP of the Australian Pharmaceutical medical and scientific Professionals Association (APPA). “It’s c...
Source: EyeForPharma - September 16, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Survey results: Accelerating digital transformation during COVID-19
COVID-19 has placed the life sciences industry in Europe under extreme pressure, testing it like no other event. Lockdowns have shocked the system and exposed shortcomings, forcing every function to evaluate and adapt its roles and responsibilities almost overnight.  But the pandemic has also accelerated a number of trends, not least the adoption of digital engagement. Pharma has acted on plans that might have taken years to put into effect, pre-pandemic and has, instead, implemented them almost overnight.  While the extent of these changes driven by the pandemic is not yet clear, there is no doubt that they wi...
Source: EyeForPharma - September 4, 2020 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.    But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures?  " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on ...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.    But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures?  " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on ...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

The future of medical congresses
Remember when pharma invested an enormous amount of time, effort and money into attending medical congresses around the world?    In the pandemic-blighted present, where all such global physical events have been put on hold, it seems an age away.    Many organisations – Reuters Events Pharma and ASCO to name but two - took immediate action and successfully transitioned their events to a digital format in record time; others were more risk-averse and chose to postpone events pending more certainty.  So what's going to happen to medical congresses now? Christoph Schmidt, former Global H...
Source: EyeForPharma - August 18, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

The future of medical congresses
Remember when pharma invested an enormous amount of time, effort and money into attending medical congresses around the world?    In the pandemic-blighted present, where all such global physical events have been put on hold, it seems an age away.    Many organisations – Reuters Events Pharma and ASCO to name but two - took immediate action and successfully transitioned their events to a digital format in record time; others were more risk-averse and chose to postpone events pending more certainty.  So what's going to happen to medical congresses now? Christoph Schmidt, former Global H...
Source: EyeForPharma - August 18, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

The future of medical congresses
Remember when pharma invested an enormous amount of time, effort and money into attending medical congresses around the world?    In the pandemic-blighted present, where all such global physical events have been put on hold, it seems an age away.    Many organisations – Reuters Events Pharma and ASCO to name but two - took immediate action and successfully transitioned their events to a digital format in record time; others were more risk-averse and chose to postpone events pending more certainty.  So whither medical congresses now? Christoph Schmidt, former global head of commercial ...
Source: EyeForPharma - August 18, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Webinars: Engaging at scale now and tomorrow
Almost overnight, webinars have become a key resource for pharma during the COVID-19 pandemic.  In May for example, Reuters Events Pharma witnessed the biggest virtual audience of any of its online events, when 3000 attendees joined the webinar on “The new normal of HCP engagement.”    It was just one demonstration of the powerful reach webinars can have. In March webinar use soared across multiple industries – a huge increase in frequency from the same time last year when audiences typically avoided Mondays and Fridays for online events.  The benefits of webinars A chief advan...
Source: EyeForPharma - July 21, 2020 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Patient centricity: Mind the capacity gap
Pharmaceutical companies and regulators are in need of increasing amounts of input from patients throughout the entire product development lifecycle, from identifying what questions to ask in the earliest stages of research through clinical development to approval.    This usually means partnering with patient organisations and advocacy groups but pharma ’s ambitions here frequently come up against a problem. Very often, both industry and patient organisations are not set up to participate in these processes – with industry lacking systematic processes and patient advocates the required training and ...
Source: EyeForPharma - July 21, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

What patients need right now
  Lockdown is a “prison like” experience, for Londoner Annabelle Ume, who suffers from myalgic encephalomyelitis. “It’s very similar to being trapped in a bunker with no access outside,” says Ume.   Many other fellow sufferers are enduring pandemic enforced isolation without much hope. “They are staying in limbo until help is available and adapting to the worsening of their health conditions,” says Ume. “You just try to make mental peace with it because the physical can’t be addressed at this time.” COPD sufferer John Linnell from Wisconsin i...
Source: EyeForPharma - July 7, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Building the medical affairs organisation of tomorrow
Medical affairs has a lot on its plate. As the pharma model has been shifting from primary-care, blockbuster-drug discovery through to more specialised medicine and gene therapy, the science has naturally become more complicated. ‘  The rise of artificial intelligence and big data means evidence generation now goes far beyond interventional studies, while the environment continues to demand more discussion around value and pricing.    Unwrapping complex science and value makes for a challenging remit for medical – without adding the shifting demands caused by the changing working patterns and g...
Source: EyeForPharma - June 15, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Building the medical affairs organisation of tomorrow
Medical affairs has a lot on its plate. As the pharma model has been shifting from primary-care, blockbuster-drug discovery through to more specialised medicine and gene therapy, the science has naturally become more complicated. ‘  The rise of artificial intelligence and big data means evidence generation now goes far beyond interventional studies, while the environment continues to demand more discussion around value and pricing.    Unwrapping complex science and value makes for a challenging remit for medical – without adding the shifting demands caused by the changing working patterns and g...
Source: EyeForPharma - June 15, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Digital success doesn ’t start with the tech
  We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.    There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.   But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Ka...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Digital success doesn ’t start with the tech
  We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.    There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.   But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Ka...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Digital success doesn ’t start with the tech
  We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.    There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.   But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Ka...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Seizing the moment in digital
  One of the most remarkable changes driven by the pandemic has been the rapid transition from face-to-face interaction to digital communication across every aspect of our lives. Even the most tech-phobic among us have been forced to embrace what digital technology has to offer.  This huge shift across all demographics and geographies could provide an unforeseen benefit to pharma, an industry that has been ripe for different types of engagement, but which has until now been held back from embracing them. The pandemic is accelerating the rollout of digital of platforms and services, says Abel Archundia, SVP...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Seizing the moment in digital
  One of the most remarkable changes driven by the pandemic has been the rapid transition from face-to-face interaction to digital communication across every aspect of our lives. Even the most tech-phobic among us have been forced to embrace what digital technology has to offer.  This huge shift across all demographics and geographies could provide an unforeseen benefit to pharma, an industry that has been ripe for different types of engagement, but which has until now been held back from embracing them. The pandemic is accelerating the rollout of digital of platforms and services, says Abel Archundia, SVP...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Seizing the moment in digital
  One of the most remarkable changes driven by the pandemic has been the rapid transition from face-to-face interaction to digital communication across every aspect of our lives. Even the most tech-phobic among us have been forced to embrace what digital technology has to offer.  This huge shift across all demographics and geographies could provide an unforeseen benefit to pharma, an industry that has been ripe for different types of engagement, but which has until now been held back from embracing them. The pandemic is accelerating the rollout of digital of platforms and services, says Abel Archundia, SVP...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Michel Pairet, Member of Board of Managing Directors at Boehringer Ingelheim on COVID-19 research
Pr écis: eyeforpharma speaks to Michel Pairet, Member of Board of Managing Directors at Boehringer Ingelheim on their COVID-19 research.YouTube URL: https://www.youtube.com/watch?v=fN9Q6bEebMM&feature=youtu.beVideo Thumbnail Image: Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercial (Source: EyeForPharma)
Source: EyeForPharma - April 29, 2020 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Michel Pairet, EVP at Boehringer Ingelheim on COVID-19 research
Pr écis: eyeforpharma speaks to Michel Pairet, EVP at Boehringer Ingelheim on their COVID-19 research.YouTube URL: https://www.youtube.com/watch?v=-PcjUccZly4&feature=youtu.beVideo Thumbnail Image: Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercial (Source: EyeForPharma)
Source: EyeForPharma - April 29, 2020 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Customer centricity in a changed world
  Few or no reps on the road, patients confined en masse to their homes and a healthcare and economic emergency of which we can still only guess the scale and duration.    It is a situation that pharma ’s marketing folk never expected, never planned for and one which our panel discuss in depth on day one of eyeforpharma’s Philadelphia Virtual conference in the panel session on customer centricity. Marketing departments face a daunting challenge. More used to planning for slowly emerging trends, they are being forced by the pandemic situation to react in real time to increase their digital ...
Source: EyeForPharma - April 20, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Customer centricity in a changed world
  Few or no reps on the road, patients confined en masse to their homes and a healthcare and economic emergency of which we can still only guess the scale and duration.    It is a situation that pharma ’s marketing folk never expected, never planned for and one which our panel discuss in depth on day one of eyeforpharma’s Philadelphia Virtual conference in the panel session on customer centricity. Marketing departments face a daunting challenge. More used to planning for slowly emerging trends, they are being forced by the pandemic situation to react in real time to increase their digital ...
Source: EyeForPharma - April 20, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Customer centricity in a changed world
  Few or no reps on the road, patients confined en masse to their homes and a healthcare and economic emergency of which we can still only guess the scale and duration.    It is a situation that pharma ’s marketing folk never expected, never planned for and one which our panel discuss in depth on day one of eyeforpharma’s Philadelphia Virtual conference in the panel session on customer centricity. Marketing departments face a daunting challenge. More used to planning for slowly emerging trends, they are being forced by the pandemic situation to react in real time to increase their digital ...
Source: EyeForPharma - April 20, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Breaking new ground in healthcare data
  The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.  Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma.  “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).  Pharma, healthcare provider...
Source: EyeForPharma - April 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Breaking new ground in healthcare data
  The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.  Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma.  “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).  Pharma, healthcare provider...
Source: EyeForPharma - April 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Breaking new ground in healthcare data
  The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.  Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma.  “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).  Pharma, healthcare provider...
Source: EyeForPharma - April 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.  George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,&r...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.  George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,&r...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.  George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,&r...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Up close and personal: The Thomas D ’Hooghe story
While his friends were easing into retirement, Thomas D ’Hooghe MD, 55, was sleepless with excitement at the thought of reinventing himself by jumping from academia to pharma.   It is a move he would recommend to anyone. “It was the best thing I ever did,” says the Vice-President and Head Global Medical Affairs, Fertility at Merck, sitting down with me and sharing his thoughts about passion, purpose, leading people and making a difference.  Origins Working in healthcare was always in his blood. In high school it was never a question; D ’Hooghe would study medicine. It was an id...
Source: EyeForPharma - April 14, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Up close and personal: The Thomas D ’Hooghe story
While his friends were easing into retirement, Thomas D ’Hooghe MD, 55, was sleepless with excitement at the thought of reinventing himself by jumping from academia to pharma.   It is a move he would recommend to anyone. “It was the best thing I ever did,” says the Vice-President and Head Global Medical Affairs, Fertility at Merck, sitting down with me and sharing his thoughts about passion, purpose, leading people and making a difference.  Origins Working in healthcare was always in his blood. In high school it was never a question; D ’Hooghe would study medicine. It was an id...
Source: EyeForPharma - April 14, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Up close and personal: The Thomas D ’Hooghe story
While his friends were easing into retirement, Thomas D ’Hooghe MD, 55, was sleepless with excitement at the thought of reinventing himself by jumping from academia to pharma.   It is a move he would recommend to anyone. “It was the best thing I ever did,” says the Vice-President and Head Global Medical Affairs, Fertility at Merck, sitting down with me and sharing his thoughts about passion, purpose, leading people and making a difference.  Origins Working in healthcare was always in his blood. In high school it was never a question; D ’Hooghe would study medicine. It was an id...
Source: EyeForPharma - April 14, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Digital Content opportunities
Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercialImage: URL: https://eloqua.eyeforpharma.com/LP=27091?extsource=efp_websiteExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - April 13, 2020 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

From reactive to predictive: Concerto ’s new compositions
In his 2016 book Healthcare Disrupted, Dr Jeff Elton sketched out how healthcare would move from being reactive to proactive thanks to the ubiquity of electronic health records (EHRs) and other datasets.   That future is now upon us, says Elton, CEO of precision oncology business Concerto HealthAI. whose mission is to combine RWE and AI to drive better insights and patient outcomes. The firm, which recently raised $150m to invest in growing ‘next-generation’ clinical research, is now busy putting technologies and tools into hundreds of life science companies and clinical settings to ask questions of r...
Source: EyeForPharma - April 10, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Moving remote: the post-pandemic clinical trial
The restrictions on movement and normal interaction owing to COVID-19 pose a distinct challenge to the traditional clinical trial model, as patients, investigators and clinical staff are either confined to their homes or seeking to avoid healthcare settings.    Those running clinical trials over the past weeks have had to adapt rapidly by fast-tracking digital capabilities to ensure continued delivery. With the future of existing trials hanging in the balance, some have been pivoting to remote delivery – sometimes in the space of under a week.   Speaking at eyeforpharma Virtual, a digital versio...
Source: EyeForPharma - April 3, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news